Welcoming new board and committee members
We’re excited to announce some fantastic new additions to both our Board of Directors and our Board’s Patient Services Committee. … Continue reading
Latest Updates
The One in a Million Benefit: Helping give others with chordoma a future
Chordoma caregiver and fundraiser Noreen Potempa gave an inspiring talk at our Chordoma Community Conference at Northwestern Medicine in Chicago … Continue reading
Create your own Facebook fundraiser to support the chordoma community
Five easy steps to start a Facebook Fundraiser Click Fundraisers in the left menu of your Facebook News Feed Click … Continue reading
Behind the Changing Landscape of Chordoma Research and Treatment with Joan Levy, PhD
Originally published on the Cancer Research Institute blog. By Arthur N. Brodsky, PhD Sarcomas are an aggressive type of … Continue reading
Sites for Epizyme’s tazemetostat trials continue to reopen to enrollment
In the ten months since the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold it placed on … Continue reading
A Patient Perspective: Susan Garbett
Chordoma survivor and advocate Susan Garbett gave an impassioned talk during last month’s Chordoma Community Conference at Northwestern Medicine in … Continue reading
Videos and key takeaways from the 2019 Chordoma Community Conference
On June 8th, more than 90 patients and caregivers from 21 states gathered in Chicago for our 2019 Chordoma Community … Continue reading
Cancer Research Institute and Chordoma Foundation partner to advance immunotherapy research in rare cancer
The Cancer Research Institute (CRI) and Chordoma Foundation announced today that they have established a research partnership to advance treatment … Continue reading
CF Annual Report: More progress, more hope
We are excited to share our latest Annual Report, which details how your support made more progress possible in 2018 than … Continue reading
Positive result from ongoing BN-Brachyury clinical trial prompts expansion
We are excited to share a promising milestone in the Foundation-supported Phase 2 BN-Brachyury trial. Yesterday, we received confirmation from … Continue reading